Spruce Biosciences (SPRB)

• Market cap: $15.6M
• 1 day: -5.63%
• 5 days: -3.21%
• 1 month: -26.30%
• 3 months: -11.38%
• 6 months: -30.11%
• Year to date: -87.25%
• 1 year: -84.78%
• 5 years: -97.78%
• 10 years: -97.78%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Employees: 22

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

800% more call options, than puts

Call options by funds: $9K | Put options by funds: $1K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

7.34% less ownership

Funds ownership: 40.27% [Q2] → 32.93% (-7.34%) [Q3]

22% less funds holding

Funds holding: 37 [Q2] → 29 (-8) [Q3]

26% less capital invested

Capital invested by funds: $8.6M [Q2] → $6.4M (-$2.2M) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

89% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 9

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 297% upside
• Avg. target: $2.25 496% upside
• High target: $3 695% upside

2 analyst ratings

• positive: 0 0%
• neutral: 2 100%
• negative: 0 0%

JMP Securities Jonathan Wolleben 44% 1-year accuracy 33 / 75 met price target	695% upside $3	Market Perform Downgraded	11 Dec 2024
RBC Capital Gregory Renza 38% 1-year accuracy 31 / 82 met price target	297% upside $1.50	Sector Perform Reiterated	11 Dec 2024